2025-524001-33-00招募中2 期
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 128
- 试验地点
- 128
研究概览
简要总结
To evaluate the efficacy of IMVT-1402 as assessed by maintenance of euthyroidism, off ATD, and off IMVT-1402 for 52 weeks in Group A Participants
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503.
排除标准
- •Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study
研究组 & 干预措施
IMVT-1402
Test
干预措施: IMVT-1402 (Drug)
研究者
Immunovant Clinical Trials
Scientific
Immunovant Sciences GmbH
研究点 (128)
Loading locations...
相似试验
招募中
3 期
A phase III, randomized, controlled, open label,
no profit, single-center intervention study to
compare the effect of a conservative
(antithyroid drugs) and an ablative
approach (radioiodine or total
thyroidectomy) for the treatment of
hyperthyroidism in patients with Graves’
disease and moderate-to-severe and active
Graves’ Orbitopathy (GO) treated with
intravenous glucocorticoids (ABLAGO Study)2024-518452-23-00Azienda Ospedaliero Universitaria Pisana52
招募中
2 期
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Grave’s Disease2024-516020-33-00Immunovant Sciences GmbH158
招募中
2 期
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye DiseaseThyroid Eye DiseaseNCT07438405Amgen30
Enrolling By Invitation
2 期
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)NCT07286006Immunovant Sciences GmbH372
尚未招募
2 期
T4/T3 Therapy in HypothyroidismNCT07424183University of Pennsylvania60